dramatically with the passage of the Government Performance and Results Act (GPRA) in 1993. GPRA focuses new attention on the quality of outcome measures used to collect information about publicly funded programs. Programs that provide services to persons who are homeless and have serious mental illnesses are facing greater need to document their effectiveness. These outcome data will ultimately be used in responding to Congressional and HHS oversight, GPRA requirements, and the requests of other governmental levels, managed care companies, and private funding sources.

The project will test the appropriateness and feasibility of selected indicators to measure the outcome of services to persons who are homeless and have serious mental illnesses. Outcome measures to be evaluated include housing status,

sobriety or drug-free status, mental health treatment status, enrollment in an educational program, and employment.

In addition, the project will evaluate process measures pertaining to outreach, service delivery and linkage stages of intervention. These process indicators include the type of contact (i.e., referrals, walk-ins, fixed outreach, and mobile outreach); whether the person contacted agreed to services, reasons for any non-enrollment, and referral to, and provision of, specific services.

The project will test these outcome and process measures in a total of approximately six provider agencies in each of five participating States. The findings of the pilot test will serve as the basis for recommendations for a voluntary national implementation of data collection in similar programs, nationwide. It will also test the

feasibility of compiling such data in a central data collection point.

Local providers will report information on services provided to individuals served. Providers will report aggregate information from their records for all new clients during a one-month period. Information will be reported on the initial client contact, on services clients receive over the next six months and on client outcomes at the end of six months. In addition, half of the provider agencies will report client followup information at a period 60 days after the conclusion of the six-month period. It is anticipated that this information will be collated from existing provider records. Data will be submitted to the central data point in aggregate form, not by individual client. Projected response burden for the project is summarized in the table below.

	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per response	Estimated total annual burden hours requested
Initial and six-month aggregate report	30 15	1 1	10 10	300 150
Total	30			450

Send comments to Nancy Pearce, SAMHSA Reports Clearance Officer, Room 16–105, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received within 60 days of this notice.

Dated: December 29, 2000.

Richard Kopanda,

Executive Officer, SAMHSA.

[FR Doc. 01–309 Filed 1–4–01; 8:45 am]

BILLING CODE 4162-20-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS. **ACTION:** Notice.

SUMMARY: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal

Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This Notice is also available on the internet at the following website: http://www.health.org/workplace

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, 5600 Fishers Lane, Rockwall 2 Building, Room 815, Rockville, Maryland 20857; Tel.: (301) 443–6014, Fax: (301) 443–3031

Special Note: Please use the above address for all surface mail and correspondence. For all overnight mail service use the following address: Division of Workplace Programs, 5515

Security Lane, Room 815, Rockville, Maryland 20852.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories

- meet the minimum standards set forth in the Guidelines:
- ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414–328–7840/800– 877–7016 (Formerly: Bayshore Clinical Laboratory)
- Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901–794–5770/888–290–1150
- Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, 615–255–2400
- Alabama Reference Laboratories, Inc., 543 South Hull St., Montgomery, AL 36103, 800–541–4931 / 334–263–5745
- Alliance Laboratory Services, 3200 Burnet Ave., Cincinnati, OH 45229, 513–585–9000 (Formerly: Jewish Hospital of Cincinnati, Inc.)
- American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 20151, 703– 802–6900
- Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119–5412, 702–733–7866/ 800–433–2750
- Baptist Medical Center—Toxicology Laboratory, 9601 I–630, Exit 7, Little Rock, AR 72205–7299, 501–202–2783 (Formerly: Forensic Toxicology Laboratory Baptist Medical Center)
- Clinical Laboratory Partners, LLC, 129 East Cedar St., Newington, CT 06111, 860–696– 8115 (Formerly: Hartford Hospital Toxicology Laboratory)
- Clinical Reference Lab, 8433 Quivira Rd., Lenexa, KS 66215–2802, 800–445–6917
- Cox Health Systems, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800–876–3652/ 417–269–3093 (Formerly: Cox Medical Centers)
- Dept. of the Navy, Navy Drug Screening Laboratory, Great Lakes, IL, Building 38-H, P. O. Box 88–6819, Great Lakes, IL 60088– 6819, 847–688–2045/847–688–4171
- Diagnostic Services Inc., dba DSI, 12700 Westlinks Drive, Fort Myers, FL 33913, 941–561–8200/800–735–5416
- Doctors Laboratory, Inc., P.O. Box 2658, 2906 Julia Dr., Valdosta, GA 31602, 912–244– 4468
- DrugProof, Division of Dynacare/Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 206–386–2672 / 800–898–0180, (Formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.)
- DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA 18974, 215–674–9310 Dynacare Kasper Medical Laboratories *,
- Dynacare Kasper Medical Laboratories *, 14940–123 Ave., Edmonton, Alberta, Canada T5V 1B4, 780–451–3702/800–661– 9876
- ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, 662–236–2609
- Express Analytical Labs, 1301 18th Ave NW, Suite 110, Austin, MN 55912, 507–437– 7322
- Gamma-Dynacare Medical Laboratories *, A Division of the Gamma-Dynacare Laboratory Partnership, 245 Pall Mall St., London, ONT, Canada N6A 1P4, 519–679– 1630

- General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 608–267– 6267
- Integrated Regional Laboratories, 5361 NW 33rd Avenue, Fort Lauderdale, FL 33309, 954–777–0018, 800–522–0232 (Formerly: Cedars Medical Center, Department of Pathology)
- Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053, 504–361– 8989/800–433–3823 (Formerly: Laboratory Specialists, Inc.)
- LabOne, Inc., 10101 Renner Blvd., Lenexa, KS 66219, 913–888–3927/800–728–4064 (Formerly: Center for Laboratory Services, a Division of LabOne, Inc.)
- Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713–856–8288/800–800–2387
- Laboratory Corporation of America Holdings, 1904 Alexander Drive, Research Triangle Park, NC 27709, 919–572–6900/800–833– 3984, (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc., CompuChem, Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group)
- Laboratory Corporation of America Holdings, 4022 Willow Lake Blvd., Memphis, TN 38118, 866–827–8042/800–233–6339 (Formerly: LabCorp Occupational Testing Services, Inc., MedExpress/National Laboratory Center)
- Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908–526– 2400/800–437–4986 (Formerly: Roche Biomedical Laboratories, Inc.)
- Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave., Marshfield, WI 54449, 715–389–3734/800– 331–3734
- MAXXAM Analytics Inc.*, 5540 McAdam Rd., Mississauga, ON, Canada L4Z 1P1, 905–890–2555 (Formerly: NOVAMANN (Ontario) Inc.)
- Medical College Hospitals Toxicology Laboratory, Department of Pathology, 3000 Arlington Ave., Toledo, OH 43699, 419– 383–5213
- MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112, 651–636–7466/ 800–832–3244
- MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503– 413–5295/800–950–5295
- Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, Minnesota 55417, 612–725–2088
- National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661–322–4250/800–350–3515
- Northwest Drug Testing, a division of NWT Inc., 1141 E. 3900 South, Salt Lake City, UT 84124, 801–293–2300/800–322–3361 (Formerly: NWT Drug Testing, NorthWest Toxicology, Inc.)
- One Source Toxicology Laboratory, Inc., 1705 Center Street, Deer Park, TX 77536, 713– 920–2559 (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory)

- Oregon Medical Laboratories, P.O. Box 972, 722 East 11th Ave., Eugene, OR 97440–0972, 541–687–2134
- Pacific Toxicology Laboratories, 6160 Variel Ave., Woodland Hills, CA 91367, 818–598– 3110/800–328–6942 (Formerly: Centinela Hospital Airport Toxicology Laboratory
- Pathology Associates Medical Laboratories, 11604 E. Indiana Ave., Spokane, WA 99206, 509–926–2400/800–541–7891
- PharmChem Laboratories, Inc., 1505–A O'Brien Dr., Menlo Park, CA 94025, 650– 328–6200/800–446–5177
- PharmChem Laboratories, Inc., Texas Division, 7606 Pebble Dr., Fort Worth, TX 76118, 817–215–8800 (Formerly: Harris Medical Laboratory)
- Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, 913– 339–0372/800–821–3627
- Poisonlab, Inc., 7272 Clairemont Mesa Blvd., San Diego, CA 92111, 858–279–2600 / 800–882–7272
- Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 30340, 770– 452–1590 (Formerly: SmithKline Beecham Clinical Laboratories, SmithKline Bio-Science Laboratories)
- Quest Diagnostics Incorporated, 4444
 Giddings Road, Auburn Hills, MI 48326,
 248–373–9120 / 800–444–0106 (Formerly:
 HealthCare/Preferred Laboratories,
 HealthCare/MetPath, CORNING Clinical
 Laboratories)
- Quest Diagnostics Incorporated, 8000 Sovereign Row, Dallas, TX 75247 214–638– 1301 (Formerly: SmithKline Beecham Clinical Laboratories, SmithKline Bio-Science Laboratories)
- Quest Diagnostics Incorporated, 4770 Regent Blvd., Irving, TX 75063, 972–916–3376/ 800–526–0947 (Formerly: Damon Clinical Laboratories, Damon/MetPath, CORNING Clinical Laboratories)
- Quest Diagnostics Incorporated, 801 East Dixie Ave., Suite 105A, Leesburg, FL 34748, 352–787–9006x4343 (Formerly: SmithKline Beecham Clinical Laboratories, Doctors & Physicians Laboratory)
- Quest Diagnostics Incorporated, 400 Egypt Rd., Norristown, PA 19403, 610–631–4600/ 800–877–7484 (Formerly: SmithKline Beecham Clinical Laboratories, SmithKline Bio-Science Laboratories)
- Quest Diagnostics Incorporated, 506 E. State Pkwy., Schaumburg, IL 60173, 800–669– 6995/847–885–2010 (Formerly: SmithKline Beecham Clinical Laboratories, International Toxicology Laboratories)
- Quest Diagnostics Incorporated, 7470
 Mission Valley Rd., San Diego, CA 92108–
 4406, 619–686–3200/800–446–4728
 (Formerly: Nichols Institute, Nichols
 Institute Substance Abuse Testing (NISAT),
 CORNING Nichols Institute, CORNING
 Clinical Laboratories)
- Quest Diagnostics Incorporated, One Malcolm Ave., Teterboro, NJ 07608, 201– 393–5590 (Formerly: MetPath, Inc., CORNING MetPath Clinical Laboratories, CORNING Clinical Laboratory)
- Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405, 818–989–2520/ 800–877–2520 (Formerly: SmithKline Beecham Clinical Laboratories)

San Diego Reference Laboratory, 6122 Nancy Ridge Dr., San Diego, CA 92121, 800–677– 7995/858–677–7970

Scientific Testing Laboratories, Inc., 463 Southlake Blvd., Richmond, VA 23236, 804–378–9130

Scott & White Drug Testing Laboratory, 600 S. 25th St., Temple, TX 76504, 254–771– 8379/800–749–3788

S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109, 505–727– 6300/800–999–5227

South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 219–234–4176

Southwest Laboratories, 2727 W. Baseline Rd., Tempe, AZ 85283, 602–438–8507/ 800–279–0027

Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus 1210 W. Saginaw, Lansing, MI 48915 517–377–0520 (Formerly: St. Lawrence Hospital & Healthcare System)

St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma City, OK 73101, 405–272–7052

Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 2703 Clark Lane, Suite B, Lower Level, Columbia, MO 65202, 573–882–1273

Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 33166, 305–593–2260.

UNILAB 18408 Oxnard St., Tarzana, CA 91356, 818–996–7300/800–339–4299 (Formerly: MetWest-BPL Toxicology Laboratory)

Universal Toxicology Laboratories, LLC 9930 W. Highway 80, Midland, TX 79706, 915– 561–8851/888–953–8851

The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPŜA-accredited laboratories was transferred to the U.S. DHHS, with the DHHS' National Laboratory Certification Program (NLCP) contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, the DHHS will recommend that DOT certify the laboratory (Federal Register, 16 July 1996) as meeting the minimum standards of the "Mandatory Guidelines for Workplace Drug Testing" (59 Federal Register, 9 June 1994, Pages 29908–29931). After receiving the DOT certification, the laboratory will be included in the monthly list of DHHS certified laboratories and

participate in the NLCP certification maintenance program.

Richard Kopanda,

Executive Officer, Substance Abuse and Mental Health Services Administration. [FR Doc. 01–64 Filed 1–4–01; 8:45 am]
BILLING CODE 4160–20–P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Endangered Species Permit Applications

AGENCY: Fish and Wildlife Service, DOI. **ACTION:** Notice of receipt of permit applications.

SUMMARY: The following applicants have applied for a scientific research permit to conduct certain activities with endangered species pursuant to section 10(a)(1)(A) of the Endangered Species Act of 1973, as amended (16 U.S.C. 1531 *et seq.*).

Permit No. TE-036120

Applicant: Michael Stephen Powers, San Diego, California

The applicant requests a permit to take (survey by pursuit) the Quino checkerspot butterfly (*Euphydryas editha quino*) in conjunction with presence or absence surveys throughout its range for the purpose of enhancing its survival.

Permit No. TE-036065

Applicant: Korey Klutz, Chula Vista, California

The applicant requests a permit to take (survey by pursuit) the Quino checkerspot butterfly (*Euphydryas editha quino*) in conjunction with presence or absence surveys throughout its range for the purpose of enhancing its survival.

Permit No. TE-027736

Applicant: David Erik LaCoste, Ramona, California

The permittee requests a permit amendment to take (survey by pursuit) the Quino checkerspot butterfly (*Euphydryas editha quino*) in conjunction with presence or absence surveys throughout its range for the purpose of enhancing its survival.

Permit No. TE-036034

Applicant: Tierra Data Systems, Escondido, California

The applicant requests a permit to remove and reduce to possession specimens of *Arctostaphylos glandulosa* ssp. *crassifolia* (Del Mar manzanita),

Chorizanthe orcuttiana (Orcutt's spineflower), and Fremontodendron mexicanum (Mexican flannelbush) in conjunction with collecting voucher specimens throughout each species' range for the purpose of enhancing their survival.

Permit No. TE-807078

Applicant: Point Reyes Bird Observatory, Stinson Beach, California

The permittee requests an amendment to extend the geographic area and take (harass, capture and band) the California least tern (*Sterna antilluarum browni*) in conjunction with monitoring throughout the Oakland-San Francisco Bay area in California for the purpose of enhancing its survival.

This application for the California least tern was published in the **Federal Register** on June 20, 2000, for Alameda County, California.

Permit No. TE-035879

Applicant: Wildlands, Inc., Citrus Heights, California

The applicant requests a permit to take (harass by survey, collect and sacrifice) the Conservancy fairy shrimp (Branchinecta conservatio), longhorn fairy shrimp (Branchinecta longiantenna), vernal pool tadpole shrimp (Lepidurus packardi), San Diego fairy shrimp (Brachinecta sandiegonensis), and the Riverside fairy shrimp (Streptocephalus woottoni) in conjunction with surveys and identification of conservation areas, throughout each species' range in California for the purpose of enhancing their survival.

Permit No. TE-021544

Applicant: Salavatore Zimmitti, San Diego, California

The applicant requests a permit to take (harass by survey, collect and sacrifice) the Conservancy fairy shrimp (Branchinecta conservatio), longhorn fairy shrimp (Branchinecta longiantenna), vernal pool tadpole shrimp (Lepidurus packardi), San Diego fairy shrimp (Brachinecta sandiegonensis), and the Riverside fairy shrimp (Streptocephalus woottoni) in conjunction with surveys and identification of conservation areas, throughout each species' range in California for the purpose of enhancing their survival.

Permit No. TE-035514

Applicant: Kevin J. Roe, University of Alabama, Tuscaloosa, Alabama

The applicant requests a permit to take (collect and sacrifice) the California